Abbott Laboratories ABT financials

Healthcare & Pharma · Statements and segments from its SEC filings, 2007 to 2025.

Abbott Laboratories revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

revenue by segment: Medical Devices, Diagnostic Products, Nutritional Products, Established Pharmaceuticals, Other
revenue by region: United States, All Other Countries, Germany, China, Switzerland, India, Japan, United Kingdom, International, Canada, The Netherlands
operating income by segment: Medical Devices, Diagnostic Products, Nutritional Products, Established Pharmaceuticals

The numbers

Annual figures

Line	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$20.9B	$27.4B	$30.6B	$31.9B	$34.6B	$43.1B	$43.7B	$40.1B	$42B	$44.3B
Gross profit	$11.8B*	$15B*	$17.9B*	$18.7B*	$19.6B*	$24.5B*	$24.5B*	$22.1B*	$23.2B*	$25B*
Operating income	$3B	$1.6B	$3.7B	$4.5B	$5.4B	$8.4B	$8.4B	$6.5B	$6.8B	$8.1B
Net income	$1.4B	$477M	$2.4B	$3.7B	$4.5B	$7.1B	$6.9B	$5.7B	$13.4B	$6.5B
EPS (diluted)	$0.94	$0.27	$1.33	$2.06	$2.50	$3.94	$3.91	$3.26	$7.64	$3.72
Operating cash flow	$3.2B	$5.6B	$6.3B	$6.1B	$7.9B	$10.5B	$9.6B	$7.3B	$8.6B	$9.6B
Free cash flow	$2.1B*	$4.4B*	$4.9B*	$4.5B*	$5.7B*	$8.6B*	$7.8B*	$5.1B*	$6.4B*	$7.4B*
Cash & equivalents	$18.6B	$9.4B	$3.8B	$3.9B	$6.8B	$9.8B	$9.9B	$6.9B	$7.6B	$8.5B
Total debt	$20.7B	$27.7B	$19.4B	$17.9B	$18.5B	$18.1B	$16.8B	$14.7B	$14.1B	$12.9B
Gross margin	56.4%	54.7%	58.4%	58.5%	56.6%	57.0%	56.1%	55.2%	55.4%	56.4%
Operating margin	14.5%	5.7%	11.9%	14.2%	15.5%	19.6%	19.2%	16.2%	16.3%	18.2%
Net margin	6.7%	1.7%	7.7%	11.6%	13.0%	16.4%	15.9%	14.3%	31.9%	14.7%

Latest quarters

Line	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$10.4B	$10.6B	$11B*	$10.4B	$11.1B	$11.4B	$11.5B*	$11.2B
Gross profit	$5.8B*	$5.9B*	$6B*	$5.9B*	$6.3B*	$6.3B*	$6.5B*	$6.3B*
Operating income	$1.7B	$1.9B	$1.9B*	$1.7B	$2.1B	$2.1B	$2.3B*	$1.3B
Net income	$1.3B	$1.6B	$9.2B*	$1.3B	$1.8B	$1.6B	$1.8B*	$1.1B
EPS (diluted)	$0.74	$0.94	$5.26*	$0.76	$1.01	$0.94	$1.02*	$0.61
Operating cash flow	$2B*	$2.7B*	$2.9B*	$1.4B	$2B*	$2.8B*	$3.3B*	$1.3B
Free cash flow	$1.4B*	$2.1B*	$2.1B*	$933M*	$1.5B*	$2.3B*	$2.6B*	$916M*
Cash & equivalents	$7B	$7.6B	$7.6B	$6.5B	$7B	$7.5B	$8.5B	$6.8B
Total debt	$14.8B*	$15B*	$14.1B	$13.2B*	$13.4B*	$12.9B*	$12.9B	$34B*
Gross margin	55.6%	55.8%	55.0%	56.9%	56.4%	55.4%	57.0%	56.2%
Operating margin	16.1%	17.5%	17.4%	16.3%	18.4%	18.1%	19.6%	12.0%
Net margin	12.5%	15.5%	84.1%	12.8%	16.0%	14.5%	15.5%	9.6%

Revenue by segment

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Medical Devices	$10.3B	$11.4B	$12.2B	$11.8B	$14.4B	$14.7B	$16.9B	$19B	$21.4B
Diagnostic Products	$5.6B	$7.5B	$7.7B	$10.8B	$15.6B	$16.6B	$10B	$9.3B	$8.9B
Nutritional Products	$6.9B	$7.2B	$7.4B	$7.6B	$8.3B	$7.5B	$8.2B	$8.4B	$8.5B
Established Pharmaceuticals	$4.3B	$4.4B	$4.5B	$4.3B	$4.7B	$4.9B	$5.1B	$5.2B	$5.5B
Other	$237M	$62M	$57M	-	-	-	-	-	-

Revenue by region

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
United States	$9.7B	$10.8B	$11.4B	$13B	$16.6B	$18.1B	$15.5B	$16.3B	$17.1B
All Other Countries	$9.9B	$11.2B	$11.5B	$12.8B	$15.5B	$14.8B	$14.2B	$14.8B	$16B
Germany	$1.4B	$1.6B	$1.8B	$2.1B	$2.6B	$2.3B	$2.3B	$2.5B	$2.8B
China	$2.1B	$2.3B	$2.3B	$2B	$2.4B	$2.1B	$2.3B	$2.1B	$1.9B
Switzerland	$841M	$1B	$1.1B	$1.1B	$1.3B	$1.3B	$1.6B	$1.7B	$1.9B
India	$1.2B	$1.3B	$1.4B	$1.3B	$1.6B	$1.6B	$1.8B	$1.8B	$1.9B
Japan	$1.3B	$1.3B	$1.4B	$1.4B	$1.7B	$1.9B	$1.5B	$1.4B	$1.5B
United Kingdom	-	-	-	-	-	-	$991M	$1.2B	$1.3B
Canada	-	-	-	$841M	$1.4B	$1.3B	-	-	-
The Netherlands	$929M	$930M	$975M	-	-	-	-	-	-

Operating income by segment

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Medical Devices	$3B	$3.5B	$3.8B	$3B	$4.5B	$4.4B	$5.3B	$6.2B	$7.2B
Diagnostic Products	$1.5B	$1.9B	$1.9B	$3.7B	$6.3B	$6.7B	$2.4B	$2.1B	$1.7B
Nutritional Products	$1.6B	$1.7B	$1.7B	$1.8B	$1.8B	$706M	$1.3B	$1.5B	$1.6B
Established Pharmaceuticals	$848M	$894M	$904M	$794M	$889M	$1B	$1.2B	$1.2B	$1.3B

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from Abbott Laboratories's own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on Abbott Laboratories or see all companies.